Researchers at King's College London have found that Metformin, a common diabetes drug, can help control inflammation and sugar levels, potentially preventing

gum disease as well as systemic conditions like diabetes and obesity. This discovery highlights the connection between oral and overall health, particularly in managing diseases that affect people globally.

Gum diseases, often linked to diabetes and obesity, are common and can start as early as age 30. Current treatments focus on deep cleaning and antibiotics but do not address systemic diseases. Metformin, however, has shown potential in preventing bone loss and reducing inflammation during gum disease, which could provide broader health benefits.

In a recent clinical trial, Metformin improved gum health and helped control sugar levels and inflammation in patients without diabetes. This suggests that it may be effective for gum disease prevention in a wider population. The drug is inexpensive, making it a viable option for large-scale use.

By using Metformin, the study suggests that both oral and systemic health can be improved. This could lead to healthier aging and better prevention of related conditions like diabetes and obesity.

Given its low cost and global availability, Metformin offers a promising solution to help people maintain better oral health and prevent broader health issues, starting with simple changes in oral care.